Lv1
70 积分 2025-10-21 加入
Firms’ connections and cluster opportunity. The case of biotechnology in the Community of Madrid
4天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2个月前
已完结
Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study
2个月前
已完结
Fluctuating Voriconazole Concentrations during Extracorporeal Membrane Oxygenation
2个月前
已完结
Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial
2个月前
已关闭
Optimizing evaluation of gastroesophageal reflux with atypical symptoms: Cost-effectiveness and cost-minimalization analysis
2个月前
已关闭
EE528 Comparative Effectiveness Modeling of an Anti-Pd-1 Antibody Drug Intervention for Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the U.S
3个月前
已完结
Getting the Job Done: Alternative Policy Instruments
3个月前
已完结
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
4个月前
已完结
皖公网安备34019202002308
